

Public Health Link

From the Chief Medical Officer for Wales

Distribution: As Appendix 1

From: Dr Frank Atherton, Chief Medical Officer for Wales

Date: 19 February 2021

Reference: CEM/CMO/2021/10

Category: Immediate (cascade within 24 hours)

Title: Interleukin-6 Inhibitors (Tocilizumab Or Sarilumab) For Hospitalised Patients With Covid-19 Pneumonia (Adults)

Dear colleagues,

NHS trusts/health boards are recommended to consider prescribing a single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following the announcement of the findings of the RECOVERY trial. Sarilumab continues to be recommended for critically ill patients being treated with non-invasive ventilation or invasive mechanical ventilation, who have not already received tocilizumab.

Yours sincerely



DR FRANK ATHERTON

To: Health Boards and NHS Trusts:

Chief Executives
Medical Directors for onward distribution to:
Hospital Doctors

Nurse Directors
Hospital Principals and Chief Pharmacists
Directors of Public Health

To: NHS Wales Shared Services Partnership to forward to:

All General Practitioners for information

.

Cc: Public Health Wales:

Chief Executive
Director of Public Health Services
Consultants in Communicable Disease Control
Microbiologists
Consultant Epidemiologists
Vaccine Preventable Disease Programme

Cc: NHS Direct Wales
British Medical Association
Royal College of GPs
Royal College of Physicians
Academy of Medical Royal Colleges
Royal College of Nursing
Royal College of Midwives
Royal College of Paediatrics and Child Health Wales